Prospects and predictions for the cardiomyopathies.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D001021:Aortic Valve / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D006332:Cardiomegaly / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000503:physiopathology; D002312:Cardiomyopathy, Hypertrophic / Q000473:pathology; D002395:Catecholamines / Q000502:physiology; D006321:Heart / Q000502:physiology / Q000503:physiopathology; D006331:Heart Diseases / Q000145:classification*; D006333:Heart Failure / Q000145:classification / Q000209:etiology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications; D009205:Myocarditis / Q000150:complications; D009206:Myocardium / Q000473:pathology; D009210:Myofibrils; D011379:Prognosis
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines